Terumo acquires Medeon’s large bore vascular closure system for $20M

A stethoscope and paper money.
Taiwanese devicemaker Medeon sells its large bore vascular closure system to Terumo for $20 million. (iStock)

Medeon Biodesign, a Taiwanese maker of minimally invasive surgical devices, sold its large bore vascular closure system to Terumo for $20 million.

The XPro System is an automated suture-mediated closure device that simultaneously delivers two pairs of sutures during percutaneous large bore procedures, including transcatheter aortic valve replacement, endovascular aneurysm repair, thoracic endovascular aneurysm repair and percutaneous balloon aortic valvuloplasty procedures.

Under terms of the agreement, Tokyo-based Terumo will pay an upfront payment of $20 million and additional payments when certain milestones are met. The two companies will continue to collaborate on future regulatory developments of the device.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"Access site complications in large bore procedures remain a significant concern among practicing clinicians,” Yue-Teh Jang, Ph.D., chairman and CEO of Medeon, said in a statement. “Leveraging the advantages of the security of suture-mediated closure and built-in safety mechanisms, the closure system provides a better solution for the large bore procedures with excellent outcomes and rapid hemostasis.”

The XPro system has successfully undergone a CE Marking clinical study in New Zealand, Australia and Taiwan. In those studies, the device achieved immediate or rapid hemostasis at the puncture sites, resulting in improved outcomes and earlier discharge from hospitals, the company said.

Suggested Articles

A toilet seat monitoring system aims to spot the signs of heart failure in the privacy of the home, with the goal of lowering hospital readmissions.

The FDA approved a heart implant from Impulse Dynamics for patients who aren’t able to use a pacemaker or standard therapies.

Sherlock Biosciences is launching with $35 million and a two-pronged approach to improving the current state of diagnostics.